Table 3. Prior studies that evaluated SLFN11 as a prognostic or predictive biomarker in cancer patients.

Cancer type	n of patients	Drugs	Conclusions	Ref.
Ewing sarcoma	44	Not specified	Tumors with high SLFN11 mRNA levels were associated with longer RFS (p = 0.0046).	[43]
Ovarian cancer	110	Cisplatin-based chemotherapy	High SLFN11 mRNA levels were associated with better OS (p = 0.016).	[16]
Recurrent small cell lung cancer	104	Temozolomide + veliparib or placebo	Temozolomide + veliparib elicited longer PFS (5.7 v 3.6 months; p = 0.009) and OS (12.2 v 7.5 months; p = 0.014) in patients with SLFN11+ tumors vs. SLFN11- tumors.	[32]
Colorectal cancer	128	Not specified	SLFN11 promoter methylation was prognostic of poor 5-year OS and 5-year RFS (p<0.05).	[16]
Colorectal cancer	237	Oxaliplatin-based chemotherapy	Among 153 patients with KRAS-wild-type tumors, SLFN-high tumors were associated with longer OS compared to SLFN11-low tumors (p = 0.048).	[44]
Non-small cell lung cancer	22	Platinum-based chemotherapy	SLFN11 promoter hypermethylation was associated with shorter PFS (p = 0.031).	[45]
Ovarian cancer	41	Cisplatin or carboplatin	SLFN11 promoter hypermethylation was associated with shorter (OS) (p = 0.006) and PFS (p = 0.003).	[45]